• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    atai Life Sciences to Host Conference Call and Webcast to Discuss Second Quarter 2021 Financial Results and Provide Business Update

    8/9/21 6:00:00 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATAI alert in real time by email

    BERLIN, Aug. 09, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a conference call on Monday, August 16, 2021 at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2021 and provide a business update.

    To access the live conference call, please dial 877-407-3982 from the United States, or +1 (201) 493-6780 internationally, using the conference ID: 13721888. The live and archived webcast of this call will be available in the "Events" section of the atai Life Sciences website at ir.atai.life.

    About atai Life Sciences

    atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. atai's business model combines funding, technology, scientific and regulatory expertise with a focus on psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies, seeking to effectively treat and ultimately heal mental health disorders. atai's mission is to bridge the gap between what the mental healthcare system currently provides and what patients need. atai is headquartered in Berlin, with offices in New York and London. For more information, please visit www.atai.life.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including without limitation statements regarding atai's participation in upcoming conferences and presentations and similar statements of a future or forward-looking nature. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors discussed under the caption "Risk Factors" in atai's prospectus pursuant to Rule 424(b) filed with the U.S. Securities and Exchange Commission ("SEC") on June 21, 2021, as such factors may be updated from time to time in atai's other filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof and accordingly undue reliance should not be placed on such statements. atai disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, whether as a result of new information, future events or otherwise, other than to the extent required by applicable law.

    Investor Contact:

    Greg Weaver

    atai – Chief Financial Officer

    Email: [email protected]

    Media Contact:

    Anne Donohoe

    KCSA Strategic Communications

    Phone: +1 (212) 896-1265

    Email: [email protected]



    Primary Logo

    Get the next $ATAI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATAI

    DatePrice TargetRatingAnalyst
    4/4/2025Buy
    Berenberg
    11/18/2024$15.00 → $10.00Buy
    H.C. Wainwright
    4/3/2024$6.00Hold → Buy
    Maxim Group
    11/1/2022$18.00Buy
    Loop Capital
    11/30/2021$25.00Buy
    Maxim Group
    11/22/2021$40.00 → $50.00Buy
    HC Wainwright & Co.
    11/16/2021$25.00 → $24.00Outperform
    Credit Suisse
    11/16/2021$19.00 → $17.00Sector Perform
    RBC Capital
    More analyst ratings

    $ATAI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • atai Life Sciences Announces $50 Million Private Placement Financing

      NEW YORK and AMSTERDAM, July 01, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced it had entered into subscription agreements relating to the purchase of 18,264,840 ordinary shares of atai with a nominal value of €0.10 per share ("Common Shares") and pre-funded warrant to purchase 4,566,210 Common Shares (the "Pre-Funded Warrant"). The financing is expected to result in gross proceeds of approximately $50 million, before deducting placement agents' fees and other expenses. The net proceeds from the financing are expec

      7/1/25 6:05:00 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

      Study met its primary and all key secondary endpoints, and BPL-003 demonstrated rapid, robust and durable antidepressant effects with a single doseBoth 8 mg and 12 mg single doses of BPL-003 showed statistically significant and clinically meaningful reductions in depressive symptoms at all time points of the study compared to a 0.3 mg low-dose active control out to Week 8BPL-003 was generally well-tolerated at all doses, with 99% of treatment-emergent adverse events being mild or moderate, and no drug-related serious adverse events or suicide-related safety signalsMajority of patients deemed ready for discharge at the 90 minutes post-dose assessment, which suggests BPL-003 could fit within t

      7/1/25 6:00:00 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

      Strategic combination establishes a market-leading mental health company with a pipeline that includes potentially transformative, rapid-acting psychedelic assets differentiated by their convenient route of administration and short time-in-clinicCombined company will operate under the name atai Beckley with a joint leadership team and Board that leverage the deep psychedelic, drug development and CNS expertise within both organizationsTopline data from the Phase 2b study of BPL-003 in patients with treatment-resistant depression (TRD) is expected in mid-2025 - the largest controlled trial of mebufotenin (5-MeO-DMT) and the first and only controlled trial to investigate mebufotenin in the U.S

      6/2/25 6:00:00 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care